In May, researchers from Mayo Clinic reported gains in understanding of the benefit of AI-enabled ECGs, including from wearable devices. They made strides towards more effective treatment of non-Hodgkin lymphoma and nonmetastatic gastroesophageal cancer. And in news many people can use, investigators report on the results of a survey linked to the Mayo Clinic Diet.
Read more in these excerpts from May's research news releases:
The New Mayo Clinic Diet, the official dietary program developed by Mayo Clinic, released key findings this week from its Diet Mindset Assessment. This survey of over 200,000 consumers in the U.S. provided insights into their mindsets when beginning a new diet program. Survey information was compiled and reviewed by Digital Wellness, a world-leading digital health platform that powers the world's most renowned and trusted weight-loss brands.
Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1.
Researchers are now investigating whether immunotherapy benefits patients who do not have stage 4 metastatic disease. In these patients, tumors have not spread to distant organs. A study highlighting this research is published in Clinical Cancer Research.
A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). The study is published in Cancer Discovery.
Patients were enrolled by email in a decentralized, prospective study. Then they downloaded an app that securely transferred watch ECGs in the background. Study participation was high, demonstrating the possibility for a scalable tool to be developed to screen and monitor heart patients for this condition wherever they are.
The study abstract was presented as late-breaking research at the Heart Rhythm Society conference on Sunday, May 1.
Artificial intelligence-enabled electrocardiography (ECG) was recently shown to identify the presence of brief episodes of atrial fibrillation, and the ability of an AI-enabled ECG algorithm to predict atrial fibrillation up to 10 years before clinical diagnosis has been confirmed in a population-based study conducted by Mayo Clinic researchers.
A new population-based study from Mayo Clinic now offers evidence that the algorithm can help identify patients at greater risk of cognitive decline. AI-enabled ECG that shows high probability of atrial fibrillation also was associated with the presence of infarctions, or incidents of cerebral stroke, on MRI, according to the study.
Meet our researchers and check out the research and education that after 150 years, continue to provide the underpinning for the first and largest integrated, not-for-profit medical group practice.
Mayo Clinic podcasts and other discussions of research and practical patient information can be found online.
Information about many of the clinical trials available across Mayo Clinic is online as well.
Tags: AFib, artificial intelligence, atrial fibrillation, CAR-T cell therapy, Center for the Science of Health Care Delivery, clinical trials, cognitive impairment, EKG, electrocardiogram, esophageal cancer, Findings, gastric cancer, gastroesophageal cancer, heart health, immunotherapy, Innovations, Mayo Clinic Cancer Center, Mayo Clinic Proceedings, News, non-Hodgkin lymphoma, population health, Progress Updates, Research News Roundup, Rochester Epidemiology Project, stroke, wearable technology, weight loss